Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

(NY: MAIA )

3.740 -0.070 (-1.84%)
Official Closing Price Updated: 8:00 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 314,592
Open 3.810
Bid (Size) 3.680 (1)
Ask (Size) 3.850 (2)
Prev. Close 3.810
Today's Range 3.600 - 4.000
52wk Range 0.8200 - 4.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market
MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market 
Via News Direct
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
Via AB Newswire

Performance

YTD
+214.29%
+214.29%
1 Month
+39.03%
+39.03%
3 Month
+171.01%
+171.01%
6 Month
+219.66%
+219.66%
1 Year
+62.61%
+62.61%

More News

Read More
MAIA Biotechnology to Present at the BIO International Convention 2024
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q1 2024
Via InvestorPlace
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $1.00 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces $1.33 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Stock Earnings: MAIA Biotechnology Misses EPS for Q4 2023
Via InvestorPlace
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology and Nationwide Children’s Hospital Announce Presentation of THIO’s Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer
Via News Direct
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
Via Talk Markets
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
Novel Therapy Shows Promising Results In On-Going Trials, Receives 3 Orphan Drug Designations From The FDA
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
From MAIA Biotechnology
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.